This is highly relevant from a clinical–translational standpoint as it provides a compelling rationale to investigate the dual BCR–ABL1–SRC-family kinase inhibitor dasatinib in Ph+ ALL, and suggests that this agent may be more effective in Ph+ ALL than imatinib or nilotinib. This evidence concerns the gene BCR and acute lymphoblastic leukemia.